Boisson-Vidal Catherine

DR2, CNRS, Deputy Director

Research theme : Theme 1
Contact

Phone: 01 53 73 97 16

Biography

Chemist polymerist by training, I dedicated the first 17 years of my career to the biomaterials, working at the Research Laboratory of Macromolecules (CNRS, Villetaneuse, France). My work was devoted to the structure/biological properties relationships of natural and synthetic polymers (biomaterials) endowed with specific biological properties, as potential pharmaceutical agents. It was carried out with the aim of developing new therapeutics mainly in the field of hemostasis and led to the filing of 5 European or worldwide patent applications and the creation of a scientific and technical engineering company “BIORACS that became THERAPOL (SARL) Biomedical Engineering 1997-2012” dedicated to the development of devices for removing the Factor VIII inhibitors in haemophiliac patients (scientific board member (1997-1999, consulting researcher for 6 years 1997-2003) (1).

Responsible for the collaboration between IFREMER ” Département Utilisation et Valorisation des Produits de la Mer ” and our research unit over the time period 1989-2000, I have supervised many research projects with the objectives of 1- Elaborating methods to prepare antithrombotic fractions of low molecular weight fucoidan in a reproducible manner, and 2- Studying the relationship between structure and properties to optimize the fucoidan biological activities (2). This work led to the filing of 3 European or worldwide patent applications and several ANVAR and R & D programs (Fournier Laboratories).

In 2003, I progressively shifted towards the study of the proangiogenic properties of fucoidan and joined the UMRS1140 at the faculty of Pharmacy of Paris. By the meantime, I developed new therapeutic approaches based on stem cell therapy. In particular, I have developed new pre-conditioning protocols to improve stem cells incorporation into sites of neovascularization (3,4). The aim of these new projects is to increase the effectiveness of cell therapy in the treatment of ischemic diseases. This could be done through better understanding of the mechanisms involved in the mobilization, recruitment, differentiation and survival of vasculogenic stem cells, and the role played by molecules produced by the surrounding cells (5,6,7). My projects also focus on the properties of fucoidan on tissue regeneration (8,9).

These studies represent a strategic axis of both basic research to improve our knowledge of the molecular mechanism involved in the process of vasculogenesis, but also a basis for the development of new therapies for the treatment of ischemic diseases.

Education

  • Master of Science “Macromolecular and Applied Chemistry” Paris 6 University, 1981
  • PhD “Biological and medical engineering” Paris 13 University, 1984
  • Docteur d’Etat ès-Sciences Physiques « Research Supervisor Qualification » Paris 13 University, 1990

Academic, research and industrial experience

  • Research Director CNRS, Inserm UMRS1140, 2003-present
  • Unit deputy director, Inserm UMRS1140, 2011 – present
  • Research Fellow CNRS, Laboratoire de Recherche sur les Macromolécules, CNRS UMR7540, 1985-2003
  • Post-doctoral fellow, Chemistry Department, McMaster University, Hamilton, Ontario, Canada. Prof J.L. Brash, 1984-1985

Publications

  • International publications: 73, 9 book chapters, patents 5
  • H-index : 27, Sum of Times Cited: 3253 (déc 2019)
  • Direction of 34 masters 2 and of 17 PhD thesis of Paris 7 and Paris 13 Universities
  • Invited conferences (international meetings): 15, 30 lectures
  • International meetings: 72 oral communications, 92 posters.

Major publications 2020 / 2010

Targeting endothelial thioredoxin-interacting protein (TXNIP) protects from metabolic disorder-related impairment of vascular function and post-ischemic revascularisation. Alison Domingues, Catherine Boisson-Vidal, Perrine Marquet de Rouge, Blandine Dizier, Jérémy Sadoine, Virginie Mignon, Emilie Vessières, Daniel Henrion, Virginie Escriou, Pascal Bigey, Catherine Chaussain, David M Smadja, Valérie Nivet-Antoine – 2020 May – PMID: 31900750 DOI: 10.1007/s10456-019-09704-x

Ceramide 1-Phosphate Protects Endothelial Colony-Forming Cells From Apoptosis and Increases Vasculogenesis In Vitro and In Vivo. Hebe Agustina Mena, Paula Romina Zubiry, Blandine Dizier, Virginie Mignon, Fernanda Parborell, Mirta Schattner, Catherine Boisson-Vidal, Soledad Negrotto – 2019 Oct – PMID: 31434496 DOI: 10.1161/ATVBAHA.119.312766

In vivo efficacy of endothelial growth medium stimulated mesenchymal stem cells derived from patients with critical limb ischemia. Rida Al-Rifai, Philippe Nguyen, Nicole Bouland, Christine Terryn, Lukshe Kanagaratnam, Gaël Poitevin, Caroline François, Catherine Boisson-Vidal, Marie-Antoinette Sevestre, Claire Tournois – 2019 Aug 9 – PMID: 31399109 PMCID: PMC6688282 DOI: 10.1186/s12967-019-2003-3

In vitro and in vivo evaluation of a dextran-graft-polybutylmethacrylate copolymer coated on CoCr metallic stent. Cécilia Delattre, Diego Velazquez, Caroline Roques, Graciela Pavon-Djavid, Véronique Ollivier, Anna Lokajczyk, Thierry Avramoglou, Virginie Gueguen, Liliane Louedec, Giuseppina Caligiuri, Martine Jandrot-Perrus, Catherine Boisson-Vidal, Didier Letourneur, Anne Meddahi-Pelle – 2019 – PMID: 30788257 PMCID: PMC6378099 DOI: 10.15171/bi.2019.04

Osteoprotegerin Induces CD34 + Differentiation in Endothelial Progenitor Cells. Catherine Boisson-Vidal, Zahia Benslimane-Ahmim, Anna Lokajczyk, Dominique Heymann, David M Smadja – 2018 Nov 27 – PMID: 30538990 PMCID: PMC6277572 DOI: 10.3389/fmed.2018.00331

Downregulation of Microparticle Release and Pro-Inflammatory Properties of Activated Human Polymorphonuclear Neutrophils by LMW Fucoidan. João Alfredo Moraes, Ana Clara Frony, Pedro Barcellos-de-Souza, Marcel Menezes da Cunha, Thayanne Brasil Barbosa Calcia, Claudia Farias Benjamim, Catherine Boisson-Vidal, Christina Barja-Fidalgo – 2019 – PMID: 30557873 PMCID: PMC6738154 DOI: 10.1159/000494220

Acidic preconditioning of endothelial colony-forming cells (ECFC) promote vasculogenesis under proinflammatory and high glucose conditions in vitro and in vivo. Hebe Agustina Mena, Paula Romina Zubiry, Blandine Dizier, Mirta Schattner, Catherine Boisson-Vidal, Soledad Negrotto – 2018 May 2 – PMID: 29720269 PMCID: PMC5930427 DOI: 10.1186/s13287-018-0872-7

Nanohybrids with Magnetic and Persistent Luminescence Properties for Cell Labeling, Tracking, In Vivo Real-Time Imaging, and Magnetic Vectorization. Teston E, Maldiney T, Marangon I, Volatron J, Lalatonne Y, Motte L, Boisson-Vidal C, Autret G, Clément O, Scherman D, Gazeau F, Richard C. Small. 2018 Apr;14(16):e1800020. doi: 10.1002/smll.201800020. (IF 8.64)

Arterial stiffening with ultrafast ultrasound imaging gives new insight into arterial phenotype of vascular Ehlers-Danlos mouse models. Goudot, G, Papadacci C, Dizier B, Baudrie V, Ferreira I, Boisson-Vidal C, Tanter M, Jeunemaitre X, Pernot M, Messas E, Mirault T. Ultraschall in der Medizin / European Journal of Ultrasound 2018 Sep 21. doi: 10.1055/a-0599-0841 (IF 3,45)

Pulsed cavitational therapy using high-frequency ultrasound for the treatment of deep vein thrombosis on an in vitro model of human blood clot. Goudot, G, Mirault T, Arnal B, Boisson-Vidal C, Le Bonniec B, Gaussem P, Galloula A, Tanter M, Messas E, Pernot M. Phys Med Biol. 2017 Nov 21;62(24):9282-9294 (IF 2.74)

Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization. Benslimane-Ahmim Z, Pereira J, Lokajczyk A, Dizier B, Galy-Fauroux I, Fischer AM, Heymann D, Boisson-Vidal C. Cancer Lett. 2017 Jun 1;395:11-19

Type 2 diabetes alters mesenchymal stem cell secretome composition and angiogenic properties. Ribot J, Caliaperoumal G, Paquet J, Boisson-Vidal C, Petite H, Anagnostou F. J Cell Mol Med. 2017 Feb;21(2):349-363.

Resistance to anti-angiogenic therapy: a clinical and scientific current issue. Gu Y, Lu H, Boisson-Vidal C, Li H, Bousquet G, Janin A et Di Benedetto M. Med Sci (Paris). 2016 Apr;32(4):370-7.

Fucoidan Stimulates Monocyte Migration via ERK/p38 Signaling Pathways and MMP9 Secretion. Sapharikas E, Lokajczyk A, Fischer AM, Boisson-Vidal C. Mar Drugs. 2015 Jun 30;13(7):4156-4170

Oxygen tension regulates human mesenchymal stem cell (hMSC) paracrine functions. Paquet J, Deschepper M, Moya A., Logeart-Avramoglou D, Boisson-Vidal C, Petite H. Stem Cells Transl Med. 2015 Jul;4(7):809-21.

IL-34 promotes tumour progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Segaliny A*, Mohamadi A*, Dizier B, Lokajczyk, Brion R, Charrier C, Boisson-Vidal C *, Heymann D*. Int J Cancer. 2015 Jul 1;137(1):73-85 (* co-1er ou co-dernier auteurs).

Acidic preconditoning improves the proangiogenic responses of endothelial colony forming cells. Mena HA, Boisson-Vidal C, Lokajczyk A, Dizier B, Strier SE, Voto LS, Schattner M, Negrotto S. Angiogenesis. 2014 Oct;17(4):867-79

Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential. D’audigier C, Gauthier B, Yon A, Alili JM, Evrard S, Godier A, Haviari S, Dizier B, Inguimbert N, Borgel D, Bieche I, Boisson-Vidal C, Roncal C, Carmeliet P, Vidal M, Gaussem P, Smadja D. Angiogenesis. 2014 Jul;17(3):603-16.

Mechanistic study of the proangiogenic effect of osteoprotegerin. Benslimane-Ahmin Z, Poirier F, Delomenie C, Lokajczyk A, Grelac F, Galy-Fauroux I, Mohamedi A, Fischer AM, Heymann D, Lutomski D, Boisson-Vidal C. Angiogenesis. 2013 Jul;16(3):575-93

A motif within the N-terminal domain of TSP-1 specifically promotes the proangiogenic activity of endothelial colony-forming cells. Dias JV, Benslimane-Ahmim Z, Egot M, Lokajczyk A, Grelac F, Galy-Fauroux I, Juliano L, Le-Bonniec B, Takiya CM, Fischer AM, Blanc-Brude O, Morandi V, Boisson-Vidal C Biochem Pharmacol. 2012 Oct 15;84(8):1014-23.

Therapeutic effect of fucoidan-stimulated endothelial colony-forming cells in peripheral ischemia. Sarlon G, Zemani F, David L, Duong Van Huyen JP, Dizier B, Grelac F, Colliec-Jouault S, Galy-Fauroux I, Bruneval P, Fischer AM, Emmerich J, Boisson-Vidal C. J Thromb Haemost. 2012 Jan;10(1):38-48.

Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. Benslimane-Ahmin Z, Heymann D, Dizier B, Lokajczyk A, Brion R, Laurendeau I, Bièche I, Smadja D, Galy-Fauroux I, Colliec-Jouault S, Fischer AM, Boisson-Vidal C. Journal of Thrombosis and Haemostasis 2011 Apr; 9(4):834-843.

Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Smadja DM, D’Aubignier C, Bièche I, Evrard S, Mauge L, Dias JV, Laurendeau I, Marsac B, Dizier B, Wagner-Ballon O, Boisson-Vidal C, Morandi V, Duong van Huyen JP, Bruneval P., Dignat-George F., Emmerich J., and Gaussem P. Arteriosclerosis, Thrombosis and Vascular Biology 2011 Mar;31(3):551-9.

Alpha6 integrin subunit plays a major role in the proangiogenic properties of endothelial progenitor cells. Bouvard C, Gafsou B, Dizier B, Galy-Fauroux I, Lokajczyk A, Boisson-Vidal C, Fischer AM, Helley D. Arteriosclerosis, Thrombosis and Vascular Biology 2010 Aug;30(8):1569-75.

Book chapter

Boisson-Vidal C. Use of Marine Compounds to Treat Ischemic Disease. In Blue Technology: Production and Use of Marine Molecules. Part II Marine Molecules for Disease Treatment / prevention and for Biological Research (S. Bates S. Labarre, Eds), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany 2018 vol 1, chapitre 9, pp265–296.